PDGFRA and central nervous system cancer: Similarly, the RTOG 0627 phase 2 trial of dasatinib, another second-generation multi-kinase inhibitor, failed to improve outcomes in gliomas with PDGFRA overexpression by IHC.20 These findings highlight the need for further exploration of the genetic mechanisms driving aberrant PDGFRA pathway activation.